Altamira Therapeutics Ltd (FRA:2QA)
€ 948 0 (0%) Market Cap: 2.52 Mil Enterprise Value: 1.99 Mil PE Ratio: 0 PB Ratio: 0.26 GF Score: 36/100

Auris Medical Holding Ltd Acquires RNA Therapeutics Company - M&A Call Transcript

Jun 03, 2021 / 12:00PM GMT
Release Date Price: €1186.4 (+4.81%)
Operator

Thank you. Good morning, and welcome to Auris Medical's conference call. On today's call, Thomas Meyer, Auris Medical's Chairman and Chief Executive Officer; and Dr. Samuel Wickline, Auris Medical's new Chief Scientific Officer will present and discuss the company's acquisition of Trasir Therapeutics as well as their related plan for a strategic repositioning of the company. The accompanying slides can be found on our website in the Investors section.

Earlier today, Auris Medical issued a news release related to these topics. The release is available on the company's website, aurismedical.com, and have been filed with the SEC.

During today's call, Auris Medical will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes statements that address future operating, financial or business performance or the company's strategies or expectations. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot